Search | Clinical Trials Finder

Conditions: Hypertriglyceridemia, Cardiovascular Disease
Interventions: Olive oil, 4g, omega-3-carboxylic acids, 2g, omega-3-carboxylic acids, 4g; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 89
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more

Conditions: HIV Infections
Interventions: Tenofovir DF, Tenofovir alafenamide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 3
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York

Conditions: Xerostomia, Sjogren's Syndrome
Interventions: NGX267; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more

Conditions: Chronic Kidney Disease, Kidney Disease
Interventions: MK-0677, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Major Depressive Disorder
Interventions: Placebo, intermittent theta burst stimulation, intravenous citalopram hydrochloride (CIT), continuous theta burst stimulation; Drug · Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gout
Interventions: PF-06743649, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 4
States / cities: Miami, Florida • South Miami, Florida • Overland Park, Kansas

Conditions: Prostate Cancer Metastatic
Interventions: HB-302/HB-301 Alternating 2-Vector Therapy; Biological
Lead sponsor: Hookipa Biotech GmbH; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 10
States / cities: Duarte, California • San Marcos, California • Miami, Florida + 5 more

Conditions: Parkinson Disease
Interventions: Liraglutide, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 25 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcoidosis-associated Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more

Conditions: Skin Health, Hair Health
Interventions: KSM-66 Ashwagandha® capsule, Placebo Capsule(s); Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Volunteers
Interventions: Rhodiola rosea (low dose), Rhodiola rosea (high dose), Placebo capsules; Dietary Supplement
Lead sponsor: Jacksonville State University; Other
Eligibility: 18 Weeks to 40 Weeks
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Jacksonville, Alabama

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: GS-9674, Placebo to match GS-9674; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 26
States / cities: Los Angeles, California • Rialto, California • Coral Gables, Florida + 19 more

Conditions: Neonatal Staphylococcal Sepsis
Interventions: Pagibaximab (formerly BSYX-A110); Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: 3 Days to 7 Days
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, csDMARDs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more

Conditions: CDI
Interventions: Vancomycin 125 MG po BID; Drug
Lead sponsor: Creighton University; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Primary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Interventions: LNA043, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Infection Prevention
Interventions: Antibiotic-impregnated Catheters (M/R), Non-impregnated Catheters (C/S); Device
Lead sponsor: Indiana University; Other
Eligibility: Up to 17 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Premature Ejaculation
Interventions: IX-01 400 mg, Placebo, IX-01 800 mg, IX-01 1200 mg; Drug
Lead sponsor: Ixchelsis Limited; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 29
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 25 more

Conditions: Rheumatoid Arthritis
Interventions: SAN-300 0.5 mg/kg QW, SAN-300 1.0 mg/kg QW, SAN-300 2.0 mg/kg QOW, SAN-300 4.0 mg/kg QOW, SAN-300 4.0 mg/kg QW, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • El Cajon, California • Los Angeles, California + 9 more

Conditions: COVID-19
Interventions: VXA-CoV2-1.1-S, Placebo Tablets; Drug · Other
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Long Beach, California • Wichita, Kansas • Cleveland, Ohio + 1 more

Conditions: Gastric Cancer, Adenocarcinoma
Interventions: ramucirumab, Placebo, Best Supportive Care (BSC); Biological · Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 14
States / cities: Bakersfield, California • La Jolla, California • Redlands, California + 11 more

Conditions: Biliary Tract Cancer
Interventions: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin, S-1 [Tegafur/Oteracil/gimeracil]; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 760 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Otomycosis
Interventions: Miconazole (2%) oil and mineral oil, Placebo; Drug · Other
Lead sponsor: Hill Dermaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: Chula Vista, California • Louisville, Kentucky • North Charleston, South Carolina + 4 more

Search by objective public record fields.

[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 Subjects

Effects of Intravenous (IV) Citalopram Hydrochloride During Transcranial Magnetic Stimulation in Major Depressive Disorder (MDD)

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

Safety and Efficacy of Liraglutide in Parkinson's Disease

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Effects of KSM-66 Ashwagandha® (300 mg) on Skin and Hair Health in Healthy Men and Women"

Short-Term Rhodiola Rosea for Anaerobic Performance and Cognitive Function in Resistance-Trained Adults

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI

First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement

Study of Catheter-related Infections Using Antibiotic-coated Versus Conventional Catheters in Children

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)

(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis